UB
DNLI icon

UMB Bank’s Denali Therapeutics DNLI Stock Holding History

UMB Bank’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16K Hold
624
– – ﹤0.01% 1768
2026
Q1 		$12K Buy
624
+362
+138% +$7.2K ﹤0.01% 1793
2025
Q4 		$4.33K Buy
+262
New +$4.42K ﹤0.01% 2050
2025
Q2 		– Sell
-416
Closed -$5.66K – 2138
2025
Q1 		$5.66K Buy
416
+34
+9% +$651 ﹤0.01% 1724
2024
Q4 		$7.79K Hold
382
– – ﹤0.01% 1558
2024
Q3 		$11.1K Buy
+382
New +$9.47K ﹤0.01% 1443
2023
Q4 		– Sell
-306
Closed -$6.31K – 1643
2023
Q3 		$6.31K Hold
306
– – ﹤0.01% 1377
2023
Q2 		$9.03K Hold
306
– – ﹤0.01% 1315
2023
Q1 		$7.05K Hold
306
– – ﹤0.01% 1365
2022
Q4 		$9K Hold
306
– – ﹤0.01% 1327
2022
Q3 		$9K Sell
306
-138
-31% -$4.49K ﹤0.01% 1339
2022
Q2 		$13K Hold
444
– – ﹤0.01% 1305
2022
Q1 		$14K Buy
+444
New +$15.3K ﹤0.01% 1369

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UMB Bank's DNLI Position: Q2 2026 in Review

UMB Bank held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 624 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #1768.

UMB Bank first reported a position in DNLI in Q1 2022 and has held it in 13 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • UMB Bank held 624 shares of Denali Therapeutics worth $16K as of Q2 2026.
  • UMB Bank left its Denali Therapeutics share count unchanged in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of UMB Bank's portfolio in Q2 2026, its #1768 holding.
  • UMB Bank first reported a position in Denali Therapeutics in Q1 2022 and has held it in 13 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on UMB Bank's 13F filing for Q2 2026, filed 13 Aug 2026.